Say goodbye to colon cancer resistance! New treatments are expected to significantly improve prognosis
Say goodbye to colon cancer resistance! New treatments are expected to significantly improve prognosis May 24, 2018 Source: WuXi PharmaTech Recently, German researchers have discovered the cause of colon cancer resistance to existing drugs and brought new insights into the treatment of colon cancer. The study found that colon cancer consists of two different cell types, one of which is killed and the other can be replaced with each other, while combination therapy for both cell types may be more effective Tumor. The study was published in the Journal of Experimental Medicine on May 16. â–²Image source: 123RF Colon cancer is the third leading cause of cancer death in the United States. Early colon cancer can be surgically removed, but advanced disease requires more targeted therapies. Researchers studying colon cancer have long been interested in two pathways, NOTCH and MAPK. However, blocking MAPK signaling that promotes the progression of colon cancer is limited and usually only prolongs the life of the patient for several months, so there is an urgent need for targeted treatment improvements in patients with colorectal cancer. A potential alternative is to target the NOTCH signaling pathway, which inhibits MAPK signaling in bladder cancer and is thought to drive colon cancer progression. However, preliminary trials of NOTCH pathway inhibitors have so far been disappointing. A team of researchers from the Ludwig Maximilian University of Munich (LMU) studied more than 300 patients and found that colon cancer consists of two different types of cells. If one of the cells is killed, the other can be replaced. The researchers said that cells in the middle of colon tumors have active NOTCH signaling, but the MAPK signal is weak and highly proliferative. On the other hand, cells at the edge of the tumor have activated MAPK signals, but the NOTCH activity is low and seems to be in metastasis. The first stage. â–²Image source: 123RF The researchers tried to attack two pathways in the mouse model, however, they found that the single-target approach was an incomplete solution. AstraZeneca's MAPK inhibitor (selumetinib) rapidly cleared MAPK-activated cells from mice. However, subsequent NOTCH cells multiplied and compensated for the loss. After stopping treatment, some NOTCH cells formed new metastatic MAPK cells along the edge of the tumor. Treatment of mice with dibenzazepine, a compound that blocks NOTCH, has the opposite effect. After removing the NOTC active cells, the MAPK cells are left to continue to multiply. After stopping treatment, new NOTCH cells will still be produced. Targeting only NOTCH may even be harmful to colon cancer patients because it increases the number of MAPK cancer cells that are about to begin to spread. "This suggests that colon cancer may evade targeted therapy for MAPK or NOTCH signaling through reversible transformation of the pathway," said Dr. David Horst, deputy director of the LMU Pathology Institute. "But when combining the two therapies, two When cells are found, we have a strong inhibitory effect on the proliferation of tumor cells and can lead to an increase in cell death. Combination therapy can slow tumor growth and prolong survival compared to either single therapy." The German team believes its data supports "specific and simultaneous targeting" of different cells of colon cancer. Dr. Horst said: "In addition to established chemotherapy regimens, further preclinical and clinical trials can reveal whether the combination of MAPK and NOTCH inhibitors can improve the treatment of patients with colorectal cancer." We look forward to taking more trials to confirm this key idea and to develop new and effective combination therapies for colorectal cancer patients. Reference materials: [1] A 2-pronged attack could improve targeted therapies for colon cancer [2] Cell type switch helps colon cancer evade treatment, study suggests Potato,Dehydrated Potatoes,Dried Potato Cubes,Dehydrated potato Round Flakes,Air Dried Potato Jiangsu Tiankang Food Co., Ltd. , https://www.tiankangfood.com
